Get the Stockscreener App
34.26
3.38%
1.12
Pre-market:
31.05
-3.21
-9.37%
Neurogene Inc stock is traded at $34.26, with a volume of 216.67K.
It is up +3.38% in the last 24 hours and up +97.69% over the past month.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
See More
Previous Close:
$33.14
Open:
$34.46
24h Volume:
216.67K
Relative Volume:
1.22
Market Cap:
$488.96M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+14.62%
1M Performance:
+97.69%
6M Performance:
+128.40%
1Y Performance:
-22.15%
1-Day Range:
$32.83
$35.47
1-Week Range:
$29.42
$35.47
52-Week Range:
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Name
Neurogene Inc
Sector
Industry
Phone
(877) 237-5020
Address
535 W 24TH STREET, NEW YORK
Compare NGNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
34.26 | 472.97M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Craig Hallum | Buy |
| May-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Mar-21-24 | Initiated | William Blair | Outperform |
| Jan-08-24 | Initiated | H.C. Wainwright | Buy |
| Jan-05-24 | Initiated | Stifel | Buy |
| Jan-04-24 | Initiated | TD Cowen | Outperform |
View All
Neurogene Inc Stock (NGNE) Latest News
Tools to monitor Neurogene Inc. recovery probabilityWeekly Profit Summary & Consistent Return Investment Signals - newser.com
Is Neurogene Inc. stock a buy on dipsWeekly Trade Summary & AI Powered Buy and Sell Recommendations - newser.com
Will Neurogene Inc. stock outperform growth indexesWatch List & Trade Opportunity Analysis Reports - newser.com
Why Neurogene Inc. (UU8) stock could be top winnerTrade Analysis Report & Weekly Momentum Picks - newser.com
Why Neurogene Inc. stock could outperform in 2025July 2025 Retail & Free Reliable Trade Execution Plans - newser.com
Signal strength of Neurogene Inc. stock in tech scanners2025 Volume Leaders & Free Verified High Yield Trade Plans - newser.com
Why Neurogene Inc. stock remains undervaluedPortfolio Value Report & AI Powered Market Trend Analysis - newser.com
Is Neurogene Inc. (UU8) stock supported by strong fundamentalsGlobal Markets & Stepwise Trade Execution Plans - newser.com
Will Neurogene Inc. (UU8) stock keep high P E multiples2025 Pullback Review & Expert Approved Momentum Ideas - newser.com
Is Neurogene Inc. (UU8) stock a buy before new product rollout - newser.com
Why Neurogene Inc. stock remains a top recommendationQuarterly Portfolio Report & Long-Term Investment Growth Plans - newser.com
How to use a screener to detect Neurogene Inc. breakoutsBear Alert & AI Enhanced Trade Execution Alerts - newser.com
Neurogene Inc. $NGNE Shares Bought by Jennison Associates LLC - MarketBeat
Combining price and volume data for Neurogene Inc.Earnings Risk Summary & Risk Controlled Swing Trade Alerts - newser.com
Why Neurogene Inc. (UU8) stock could break out in 2025Entry Point & Entry Point Confirmation Alerts - newser.com
Price action breakdown for Neurogene Inc.Weekly Trade Summary & AI Powered Buy and Sell Recommendations - newser.com
Will Neurogene Inc. (UU8) stock profit from automation wave2025 Fundamental Recap & Weekly High Return Forecasts - newser.com
Can Neurogene Inc. (UU8) stock sustain institutional flowsJuly 2025 Big Picture & Technical Buy Zone Confirmations - newser.com
HC Wainwright & Co. Maintains Neurogene (NGNE) Buy Recommendation - Nasdaq
Neurogene price target raised to $65 from $45 at H.C. Wainwright - TipRanks
Applying big data sentiment scoring on Neurogene Inc.Weekly Market Report & Fast Moving Stock Watchlists - newser.com
Statistical indicators supporting Neurogene Inc.’s strengthJuly 2025 Closing Moves & Stepwise Entry and Exit Trade Signals - newser.com
Risk adjusted return profile for Neurogene Inc. analyzedQuarterly Earnings Report & Technical Confirmation Trade Alerts - newser.com
Neurogene Inc.’s volatility index tracking explainedJuly 2025 Breakouts & Detailed Earnings Play Strategies - newser.com
Volume spikes in Neurogene Inc. stock – what they meanMarket Rally & Scalable Portfolio Growth Methods - newser.com
What is the fair value of Neurogene Inc. stock nowMarket Activity Recap & AI Optimized Trade Strategies - newser.com
Why Neurogene Inc. stock is popular among millennialsTrade Analysis Report & Verified Swing Trading Watchlists - newser.com
Neurogene Inc Stock (NGNE) Financials Data
There is no financial data for Neurogene Inc (NGNE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):